In the 1429 patients who received a taxane, the initial taxane selected by the
investigator was:
•
Docetaxel
(n=775,
54.2%
)
•
Paclitaxel
(n=589,
41.2%
)
•
Nab-paclitaxel
(n=65,
4.5%
).
PERUSE: Global safety study
35% Stage IV at diagnosis
29% prior (neo) adjuvant trastuzumab
73% visceral disease
Bachelot, SABCS2016
